Drug Search Results
More Filters [+]


Alternative Names: mepyramine
Latest Update: 2024-03-15
Latest Update Note: Clinical Trial Update

Product Description

Mepyramine, a histamine H1 receptor inverse agonist, binds preferentially to a G protein-coupled form of the receptor and sequesters G protein (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15192105/)

Mechanisms of Action: H1 Inverse Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Bangladesh | Dominican Republic | Ecuador | France | Hong Kong | India | Indonesia | Ireland | Lebanon | Malta | Mexico | New Zealand | Pakistan | Peru | Portugal | South Africa | Spain | Taiwan | Turkey | United Kingdom | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mepyramine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events